» Articles » PMID: 30123978

Racial Disparities in Outcomes for High-grade Uterine Cancer: A California Cancer Registry Study

Overview
Journal Cancer Med
Specialty Oncology
Date 2018 Aug 21
PMID 30123978
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Endometrial cancer (EC) is the most common gynecologic malignancy. We examined factors affecting overall prognosis and survival among different racial groups diagnosed with high-grade EC.

Methods: We utilized the California Cancer Registry database (CCR) to identify women with high-grade II EC from 1998 to 2009. Using the Kaplan-Meier method, we described disease-specific survival. Survival by stage, race, and time to treatment category was compared using the log-rank test. The associations of race with disease-specific survival were modeled using Cox proportional hazards regression. Covariates were selected a priori.

Results: A total of 10 647 patients met study eligibility criteria. The majority of patients in this cohort of high-grade EC were non-Hispanic (NH) white (64.1%), followed by Hispanic (15.7%), Asian (10.4%), and NH black (9.8%). NH black women had higher incidence of certain aggressive histologic subtypes in comparison with NH whites, including serous carcinomas and carcinosarcoma. Non-Hispanic black patients had a worse 5-year disease-specific survival (DSS) when compared to other racial groups. The five-year DSS for NH black women was 54% (51%-57%), compared to NH white women 66% (65%-67%), Hispanic 67% (64%-69%), and Asians 69% (67%-72%) (P < 0.0001). This clear survival disadvantage of NH black women persisted when controlling for other factors.

Conclusions: Non-Hispanic black women have a higher incidence of more aggressive histologic subtypes even among a cohort of women high-grade EC and have a disproportionately worse disease-specific survival after controlling for factors such as age, histologic subtype, stage, time to treatment, and type of treatment.

Citing Articles

The Combined Effects of Urine Zinc, Cadmium, Mercury, Lead, and Copper on Endometrial Cancer Staging.

Haruna I, Broaddus R, Gladden A, Subedi K, Obeng-Gyasi E Int J Environ Res Public Health. 2025; 22(2).

PMID: 40003471 PMC: 11855543. DOI: 10.3390/ijerph22020245.


Uterine Carcinosarcoma-A Retrospective Cohort Analysis from a Tertiary Centre on Epidemiology, Management Approach, Outcomes and Survival Patterns.

Smyth S, Ripullone K, Zouridis A, Pappa C, Spain G, Gkorila A Cancers (Basel). 2025; 17(4).

PMID: 40002230 PMC: 11853231. DOI: 10.3390/cancers17040635.


Trends and ethnic disparity in endometrial cancer mortality in South Africa (1999-2018): A population-based Age-period-cohort and Join point regression analyses.

Olorunfemi G, Libhaber E, Ezechi O, Musenge E PLoS One. 2025; 20(1):e0313487.

PMID: 39854486 PMC: 11759400. DOI: 10.1371/journal.pone.0313487.


Five-Year Relative Survival Rates of Women Diagnosed with Uterine Cancer by County-Level Socioeconomic Status Overall and across Histology and Race/Ethnicity.

Wijayabahu A, McGee-Avila J, Shiels M, Harsono A, Arend R, Clarke M Cancers (Basel). 2024; 16(15).

PMID: 39123474 PMC: 11311553. DOI: 10.3390/cancers16152747.


The Multi-Institutional Medullary Thyroid Cancer Collaborative Registry: Can a Rare Tumor Registry Accurately Represent the Real-World Patient Population?.

Szabo Yamashita T, Williams-Perez S, Ehsan S, Mulder M, Kronenfeld D, Huang C Thyroid. 2024; 34(9):1117-1125.

PMID: 38984944 PMC: 11698660. DOI: 10.1089/thy.2024.0239.


References
1.
Oh S, Galanter J, Thakur N, Pino-Yanes M, Barcelo N, White M . Diversity in Clinical and Biomedical Research: A Promise Yet to Be Fulfilled. PLoS Med. 2015; 12(12):e1001918. PMC: 4679830. DOI: 10.1371/journal.pmed.1001918. View

2.
Talhouk A, McAlpine J . New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016; 3:14. PMC: 5154099. DOI: 10.1186/s40661-016-0035-4. View

3.
Baskovic M, Lichtensztajn D, Nguyen T, Karam A, English D . Racial disparities in outcomes for high-grade uterine cancer: A California cancer registry study. Cancer Med. 2018; 7(9):4485-4495. PMC: 6143920. DOI: 10.1002/cam4.1742. View

4.
Mahdi H, Hou H, Kowk L, Moslemi-Kebria M, Michener C . Type II endometrial cancer in Hispanic women: tumor characteristics, treatment and survival compared to non-Hispanic white women. Gynecol Oncol. 2014; 133(3):512-7. DOI: 10.1016/j.ygyno.2014.03.562. View

5.
Guttery D, Blighe K, Polymeros K, Paul Symonds R, Macip S, Moss E . Racial differences in endometrial cancer molecular portraits in The Cancer Genome Atlas. Oncotarget. 2018; 9(24):17093-17103. PMC: 5908308. DOI: 10.18632/oncotarget.24907. View